Preferred Label : Danoprevir Sodium;
NCIt definition : The sodium salt form of danoprevir, an orally bioavailable, peptidomimetic inhibitor
of hepatitis C virus (HCV) NS3/4A protease, with antiviral activity against HCV and
potential antiviral activity against SARS-CoV-2. Upon oral administration, danoprevir
binds to and blocks the activity of HCV NS3/4A protease. This prevents the cleavage
and processing of HCV viral proteins leading to the inhibition of HCV replication.
Danoprevir may also bind to and block of the activity of SARS-CoV-2 protease. This
prevents the cleavage and processing of SARS-CoV-2 viral proteins leading to the inhibition
of SARS-CoV-2 replication. NS3/4A, a chymotrypsin-like serine protease, is responsible
for cleavage at four sites of the HCV polyprotein to form the viral proteins required
for HCV replication. It plays a key role in the HCV viral replication process. HCV
infection is associated with the development of hepatocellular carcinoma (HCC). A
chymotrypsin-like protease is responsible for cleavage of the SARS-CoV-2 viral polyprotein
to form the RNA replicase-transcriptase complex, which plays a key role in the SARS-CoV-2
viral transcription and replication process.;
UNII : 217RJI972K;
InChIKey : GXYYUDQAGCVAGJ-HHGSPMIASA-M;
CAS number : 916826-48-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 916826-48-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
NCI Metathesaurus CUI : CL971529;
Origin ID : C166530;
UMLS CUI : C5238020;
Semantic type(s)
- concept_is_in_subset
